Citations

Clear

3485 citation(s) found for "Sy, Sarah".

528 REM Sleep Without Atonia in Idiopathic REM Sleep Behavior Disorder in the North American Prodromal Synucleinopathy Cohort
Feemster, John, Timm, Paul, Teigen, Luke, Faber, Sarah, Steele, Tyler, Hedtkamp, Kristina, Ju, Yo‐El S. , McCleland, Jennifer, Pelletier, Amélie , Avidan, Alon Y. , Avidan, Alon Y , McCarter, Stuart J. , Boeve, Bradley F. , Postuma, Ronald B. , Bliwise, Donald L. , Louis, Erik K. St.

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A208-A208

10.1093/sleep/zsab072.527 Get It

Abstract Introduction Idiopathic/isolated REM sleep behavior disorder (iRBD) is a prodromal alpha-synucleinopathy characterized by dream enactment behavior and REM sleep without atonia (RSWA). We sought to define quantitative RSWA diagnostic thresholds in the North American Prodromal Synucleinopathy (NAPS) Consortium cohort. We analyzed RSWA between iRBD patients across participating NAPS sleep centers, compared to normative controls, and hypothesized that previous diagnostic RSWA thresholds were overestimates. Methods All digital polysomnography files were converted to European Data Format and scored at a central laboratory (Mayo Clinic) which standardized display scoring montages, channel sensitivities, and filtering, and scripted computational analyses for visual scoring. RSWA was quantitatively analyzed in the submentalis (SM) and anterior tibialis (AT) muscles in iRBD (n=86) patients and controls (n=118) utilizing well validated visual (Mayo) and automated (RAI) methods. Parametric statistics were used to compare RSWA metrics, and RSWA thresholds were developed using receiver operating characteristic curves. Results RSWA was significantly higher for the RAI and all visual individual and combined muscle activity metrics in iRBD compared to controls (all p<0.001). Average SM phasic measures were: 14.2% (Mayo), 17.9% (McGill), 18.5% (UCLA), and 9.4% (Washington University). Average AT phasic measures at each site were: 26.7% (Mayo), 17.1% (McGill), 23.3% (UCLA), and 17.4% (Washington University). Average SM/AT ‘any’ measures at each site were: 45.4% (Mayo), 35.9% (McGill), 53.4% (UCLA), and 23.5% (Washington University). Overall cohort RBD diagnostic thresholds (AUC, specificity/sensitivity) were: SM phasic 4.9% (90.0, 82.2%/83.7%); AT phasic 7.6% (88.7%, 82.2%/81.4%) and combined SM/AT ‘any’ 13% (94.6, 83.9%/96.5%). Conclusion RSWA thresholds in the NAPS cohort were substantially lower than previously reported, suggesting previously overestimated diagnostic RSWA thresholds due to smaller, enriched patient samples and overfit statistical modeling. Confirmation of these findings in the complete NAPS cohort (n=300 iRBD patients across all 10 NAPS centers) is planned. Support (if any):
Quality of Life and Its Determinants in Patients With Adrenal Insufficiency: A Survey Study From Three Tertiary Centers in the United States
Li, Dingfeng , Suresh, Malavika, Else, Tobias , Westfall, Ashleigh, Vaidya, Anand , Brand, Sarah B. , Hamidi, Oksana , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A92-A93

10.1210/jendso/bvab048.185 Get It

Abstract Context: Quality of life (QoL) is impaired in patients with chronic adrenal insufficiency (AI) despite standard glucocorticoid (GC) replacement therapy. Current evidence on the determinants of QoL is scarce and limited in very few European countries, and how it relates to AI subtypes remains underexplored. Objective: We conducted the first survey study in patients with AI in the USA to determine the correlations between clinical parameters, adverse outcomes, patient education, socioeconomic factors, and QoL in different subtypes of AI. Design, Setting and Participants: Cross-sectional survey study of 529 patients with AI between 2015 and 2020, at three tertiary centers in the USA. Intervention: Patient-centered questionnaires. Main Outcome Measures: QoL scores using Short-Form 36. Results: Of 529 participants, 223 (42.2%) had primary AI (PAI), 190 (35.9%) had secondary AI (SAI), and 116 (21.9%) had glucocorticoid induced AI (GIAI). Median age at the time of survey was 58 years (IQR: 43–68), 342 (64.8%) were women and 483 (91.3%) were Caucasians. Median duration of AI was 6 years (IQR: 3–14.5), longest in patients with PAI (11 vs 4 years in SAI and GIAI, p=0.0001). Overall, Physical Composite Summary (PCS) score was lower than the Mental Composite Summary (MCS) (38.1±12.9 vs 46.5±11.8). Across the eight dimensions, each individual decade- and sex-adjusted Z-score (using the normative data of USA population) in patients with PAI was significantly higher than that of the other two AI subtypes (all p<0.05), although all Z-scores were still below 0. In multivariate analyses, patients were more likely to report a worse PCS score (<40) if they were women (OR: 3.3, CI 95%: 1.8–6.0), had SAI or GIAI (OR: 2.5, CI 95%: 1.4–4.3), had shorter duration of AI (<6 years) (OR: 2.0, CI 95%: 1.1–3.6), were treated with >25 mg hydrocortisone equivalent daily (OR: 2.3, CI 95%: 1.2–4.6), had more comorbidities related to GC excess (OR: 2.3, CI 95%: 1.3–4.0), reported higher financial burden due to AI (OR: 2.1, CI 95%: 1.3–3.6), and reported difficulties with AI management (OR: 2.5, CI 95%: 1.2–5.2). Women (OR: 2.1, CI 95%: 1.08–4.0), shorter duration of AI (OR: 2.4, CI 95%: 1.4–4.3), higher financial burden due to AI (OR: 2.3, CI 95%: 1.3–4.0), reporting difficulties with AI management (OR: 2.6, CI 95%: 1.4–4.9), and lack of family support during adrenal crisis (OR: 9.1, CI 95%: 2.3–33.3), were predictors of a worse MCS score (<40). Conclusions: Patients with AI have substantially impaired QoL despite GC replacement therapy. Certain determinants of QoL are modifiable and achievable, such as avoiding GC over-replacement, offering detailed hands-on education in self-management, more comprehensive insurance coverage, and more robust domestic support. Our study calls for a multidimensional effort from patients, clinicians, and society to improve QoL in this vulnerable patient population.
Pathology, Radiology, and Genetics of Interstitial Lung Disease in Patients With Shortened Telomeres
Cecchini, Matthew J. , Tarmey, Tara, Ferreira, Allison J., Mangaonkar, Abhishek A. , Ferrer, Alejandro, Patnaik, Mrinal M. , Wylam, Mark E. , Jenkins, Sarah M. , Spears, Grant M. , Yi, Eunhee S. , Hartman, Thomas E. , Roden, Anja C. , Ferrer, Alejandro , Scott, John P.

Mayo Clinic

American Journal of Surgical Pathology | May 3, 2021 | Volume: 45 | Issue: 7 | Pages: 871-884

10.1097/pas.0000000000001725 | PMID 33935155 Get It

Interstitial lung diseases (ILDs) in patients with shortened telomeres have not been well characterized. We describe demographic, radiologic, histopathologic, and molecular features, and p16 expression in patients with telomeres ≤10th percentile (shortened telomeres) and compare them to patients with telomere length >10th percentile. Lung explants, wedge biopsies, and autopsy specimens of patients with telomere testing were reviewed independently by 3 pathologists using defined parameters. High-resolution computed tomography scans were reviewed by 3 radiologists. p16-positive fibroblast foci were quantified. A multidisciplinary diagnosis was recorded. Patients with shortened telomeres (N=26) were morphologically diagnosed as usual interstitial pneumonia (UIP) (N=11, 42.3%), chronic hypersensitivity pneumonitis (N=6, 23.1%), pleuroparenchymal fibroelastosis, fibrotic nonspecific interstitial pneumonia, desquamative interstitial pneumonia (N=1, 3.8%, each), and fibrotic interstitial lung disease (fILD), not otherwise specified (N=6, 23.1%). Patients with telomeres >10th percentile (N=18) showed morphologic features of UIP (N=9, 50%), chronic hypersensitivity pneumonitis (N=3, 16.7%), fibrotic nonspecific interstitial pneumonia (N=2, 11.1%), or fILD, not otherwise specified (N=4, 22.2%). Patients with shortened telomeres had more p16-positive foci (P=0.04). The number of p16-positive foci correlated with outcome (P=0.0067). Thirty-nine percent of patients with shortened telomeres harbored telomere-related gene variants. Among 17 patients with shortened telomeres and high-resolution computed tomography features consistent with or probable UIP, 8 (47.1%) patients showed morphologic features compatible with UIP; multidisciplinary diagnosis most commonly was idiopathic pulmonary fibrosis (N=7, 41.2%) and familial pulmonary fibrosis (N=5, 29%) in these patients. In conclusion, patients with shortened telomeres have a spectrum of fILDs. They often demonstrate atypical and discordant features on pathology and radiology leading to diagnostic challenges.
Generating a Social Media Ontology for Otology and Neurotology
Marinelli, John P. , Carlson, Matthew L. , Lustig, Lawrence R. , Kesser, Bradley W. , Antonelli, Patrick J. , Hong, Robert , Bowe, Sarah N.

Mayo Clinic

Otology & Neurotology | May 3, 2021 | Volume: 42 | Issue: 5 | Pages: 635-637

10.1097/mao.0000000000003170 | PMID 33935255 Get It

Sex‐based limits to running speed in the human, horse and dog: The role of sexual dimorphisms
Senefeld, Jonathon W. , Shepherd, John R.A. , Baker, Sarah E. , Joyner, Michael J. , Joyner, Michael J , Senefeld, Jonathon W , Baker, Sarah E

Mayo Clinic

The FASEB Journal | April 29, 2021 | Volume: 35 | Issue: 5 | Pages: No page available

10.1096/fj.202100161r | PMID 33913189 Get It

Abstract Elite performing men continue to record faster record times in running events compared to women. These sex‐based differences in running speed and endurance in humans are expected based on sexual dimorphisms that contribute to differences in the determinants of aerobic performance. Comparatively, the sexual dimorphisms contributing to sex‐based differences in elite aerobic performance are not ubiquitous across other species that compete in running events. The purpose of this review is to offer a framework and model for ongoing discussions of the physiological determinants and ultimately limits of physical performance. The records for average running speed of champion athletes were delineated by sex for thoroughbred horses, greyhound dogs, and humans. Male and female performances within each of these species are being optimized by training, nutrition, and financial incentives, and are approaching a performance maximum. For horses and greyhounds breeding also plays a role. Analysis of athletic records shows that there is a sex‐related difference of ~10% or more in elite athletic performance for humans; however, the upper limit of performance does not appear to be different between sexes for thoroughbred horses and greyhound dogs. In the context of the nil sex differences in running performance in thoroughbreds and greyhounds, we discuss the physiological role of sexual dimorphisms on sex‐specific limits to running performance. We highlight that studies on both human and animal performance in athletic events stimulate critical physiological questions and drive novel research.
“What Matters to Me”: What pediatric stem cell transplant patients want their providers to know
McCarthy, Sarah , Tarquini, Sarah, Metcalf, Brittany, Pickard, Lucy, Greenzang, Katie A. , Mack, Jennifer W. , McCarthy, Sarah R. , McCarthy, Sarah R , McCarthy, Sarah R.

Mayo Clinic

Journal of Psychosocial Oncology | April 26, 2021 | Volume: 39 | Issue: 4 | Pages: 586-593

10.1080/07347332.2021.1906376 | PMID 33900895 Get It

Shared Decision Making Tools for People Facing Stroke Prevention Strategies in Atrial Fibrillation: A Systematic Review and Environmental Scan
Roldan, Victor D. Torres , McCarthy, Sarah , Ponce, Oscar J. , Belluzzo, Tereza , Urtecho, Meritxell , Suárez, Nataly R. Espinoza , Toloza, Freddy J.K. , Thota, Anjali, Organick, Paige, Liu-Sanchez, Carolina , Jaladi, Soumya , Hargraves, Ian , Brito, Juan P. , McCarthy, Sarah R. , Torres Roldan, Victor D , Brand-McCarthy, Sarah R, Espinoza Suarez, Nataly R , Thota, Anjali D, Organick, Paige W, Barrera, Francisco, Ozanne, Elissa M , Hargraves, Ian G, Montori, Victor M , McCarthy, Sarah R , Liu-Sanchez, Carolina , Brito, Juan P , Ponce, Oscar Josue , Barrera, Francisco J. , Prokop, Larry J. , Ozanne, Elissa M. , Fagerlin, Angela , Noseworthy, Peter A. , Montori, Víctor M. , McCarthy, Sarah R.

Mayo Clinic

Medical Decision Making | April 24, 2021 | Volume: 41 | Issue: 5 | Pages: 540-549

10.1177/0272989x211005655 | PMID 33896270 Get It

Objective Shared decision making (SDM) tools can help implement guideline recommendations for patients with atrial fibrillation (AF) considering stroke prevention strategies. We sought to characterize all available SDM tools for this purpose and examine their quality and clinical impact. Methods We searched through multiple bibliographic databases, social media, and an SDM tool repository from inception to May 2020 and contacted authors of identified SDM tools. Eligible tools had to offer information about warfarin and ≥1 direct oral anticoagulant. We extracted tool characteristics, assessed their adherence to the International Patient Decision Aids Standards, and obtained information about their efficacy in promoting SDM. Results We found 14 SDM tools. Most tools provided up-to-date information about the options, but very few included practical considerations (e.g., out-of-pocket cost). Five of these SDM tools, all used by patients prior to the encounter, were tested in trials at high risk of bias and were found to produce small improvements in patient knowledge and reductions in decisional conflict. Conclusion Several SDM tools for stroke prevention in AF are available, but whether they promote high-quality SDM is yet to be known. The implementation of guidelines for SDM in this context requires user-centered development and evaluation of SDM tools that can effectively promote high-quality SDM and improve stroke prevention in patients with AF.
Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline
Kotagal, Suresh , Auger, R. Robert , Rowley, James A. , Hashmi, Sarah D., Maski, Kiran , Trotti, Lynn Marie , Watson, Nathaniel F.

Mayo Clinic

Journal of Clinical Sleep Medicine | April 23, 2021 | Volume: 17 | Issue: 9 | Pages: 1881-1893

10.5664/jcsm.9328 | PMID 34743789 Get It

Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment
Kotagal, Suresh , Auger, R. Robert , Swick, Todd J. , Rowley, James A. , Hashmi, Sarah D., Maski, Kiran , Trotti, Lynn Marie , Watson, Nathaniel F.

Mayo Clinic

Journal of Clinical Sleep Medicine | April 23, 2021 | Volume: 17 | Issue: 9 | Pages: 1895-1945

10.5664/jcsm.9326 | PMID 34743790 Get It